0000950123-21-003225 Sample Contracts
INDEMNIFICATION AGREEMENTIndemnification Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [___________________] between Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), and [___________] (“Indemnitee”).
Standard Contracts
OFFICE LEASEOffice Lease • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HSPF LA JOLLA COMMONS I INVESTORS LLC, a Delaware limited liability company (“Landlord”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SELECTED PRODUCT LICENSE AGREEMENT (AB-101)Selected Product License Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of November 21, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Re: Employment Offer LetterEmployment Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be August 19th, 2019. This offer is contingent upon references and Board approval.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of February 22, 2021, by and among Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
Agreement Confidential QA Controlled Document Master Agreement for Manufacturing Services March 16, 2020 / DCR001 AGR001.01Master Agreement for Manufacturing Services • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Amendment No. 1 to Option and License AgreementOption and License Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”), effective as of June 23, 2020, amends certain provisions of the Option and License Agreement dated September 4, 2019, between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER RESEARCH SERVICES AGREEMENT (For Selected Products)Master Research Services Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS MASTER RESEARCH SERVICES AGREEMENT (the “Agreement”) is made as of August 3, 2020 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation, having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121 (“Artiva”), and GREEN CROSS LABCELL CORPORATION, a Korean corporation, with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea (“GCLC”).
Amendment No. 1 to Master Agreement for Manufacturing ServicesMaster Agreement for Manufacturing Services • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”), effective as of June 16, 2020, amends certain provisions of the Master Agreement for Manufacturing Services dated March 16, 2020, between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and Green Cross Cell Corporation, a Korean corporation (“Manufacturer”), with its principal place of business located at 107, lhyeon-ro 30 beon-gil, Giheung- gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
MERCK PARTNERED PRODUCT RESEARCH SERVICES AND LICENSE AGREEMENTMerck Partnered Product Research Services and License Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS MERCK PARTNERED PRODUCT RESEARCH SERVICES AND LICENSE AGREEMENT (the “Agreement”) is made as of January 27, 2021 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea.
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between Artiva Biotherapeutics, Inc. and Merck Sharp & Dohme Corp.Exclusive License and Research Collaboration Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License and Research Collaboration Agreement (this “Agreement”) is effective as of January 26, 2021 (the “Effective Date”) and is entered into by and between Artiva Biotherapeutics, Inc., a corporation organized and existing under the laws of Delaware (“Company”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
Dated November 4, 2020 Affimed GmbH and Artiva Biotherapeutics, Inc. Strategic Collaboration AgreementStrategic Collaboration Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Strategic Collaboration Agreement (Agreement) is made and entered into as of November 4, 2020 (the Effective Date) by and between Affimed GmbH, a German corporation having its principal office at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (Affimed) and Artiva Biotherapeutics, Inc. (Artiva), a US corporation having its principal office at, 4747 Executive Drive #1150, San Diego, CA 92121, USA (Artiva), (Affimed and Artiva each a Party and together the Parties).
March 16th, 2019 Dr. Peter Flynn Re: Employment Offer Letter Dear PeterEmployment Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be April 15th, 2019 (the first date of your employment, the “Start Date”). This offer is contingent upon approval by the Company’s Board of Directors (the “Board”), and your successful completion of a background check to the satisfaction of the Company.
Re: Employment Offer LetterEmployment Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
On behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).
ARTIVA BIOTHERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT for THOMAS J. FARRELLExecutive Employment Agreement • March 2nd, 2021 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (this “Agreement”), is made and entered into effective as of March 1, 2019 (the “Effective Date”), by and between Thomas J. Farrell (“Executive”) and Artiva Biotherapeutics, Inc., a Delaware corporation (the “Company”).
